Life Sciences News | BioTuesdays by Kilmer Lucas IR

Executive Moves

ObsEva names Brian O’Callaghan as CEO

Brian O’Callaghan ObsEva (NASDAQ:OBSV) appointed Brian O’Callaghan as CEO, effective Dec. 1. He succeeds ObsEva’s co-founder, Ernest Loumaye, M.D., Ph.D., who is retiring from his role as CEO but will remain a...

November 9, 2020

Markets

Raymond James starts Perimeter Medical Imaging at OP; PT $3 (Canadian)

Raymond James initiated coverage of Perimeter Medical Imaging AI (TSXV:PINK) with an “outperform” rating and price target of $3 (Canadian). The stock closed at $2.19 on Nov. 6. Perimeter is commercializing its Optical...

November 9, 2020

Markets

William Blair starts Codiak BioSciences at OP

William Blair launched coverage of Codiak BioSciences (NASDAQ:CDAK) with an “outperform” rating based on the potential of the company’s novel exosome platform and clinical readouts over the next six-to-nine months...

November 9, 2020

Markets

Stifel starts AVEO Pharma at buy; PT $9

Stifel initiated coverage of AVEO Pharmaceuticals (NASDAQ:AVEO) with a “buy” rating and price target of $9. The stock closed at $5.66 on Nov. 6. AVEO is focused on the development and commercialization of targeted...

November 9, 2020

Developments

IntelGenx reports montelukast effect on neurological aging published in peer-reviewed journal

IntelGenx (TSXV:IGX; OTCQB:IGXT) reported that the peer-reviewed International Journal of Clinical Pharmacy published a study on montelukast’s effect on aging. IntelGenx is currently conducting a Phase...

November 9, 2020

Executive Moves

Marizyme names Neil Campbell as president and CEO

Marizyme (NASDAQ:MRZM) appointed Neil Campbell, Ph.D., as CEO, replacing executive chairman James Sapirstein, who has been the company’s interim CEO since September 2020. Dr. Campbell currently serves as chairman of...

November 6, 2020

Developments

Humanigen reports positive interim data from Phase 3 COVID-19 trial

Humanigen (NASDAQ:HGEN) reported positive interim results from its Phase 3 trial evaluating lenzilumab in hospitalized COVID-19 patients. Lenzilumab is an antibody that targets granulocyte-macrophage colony-stimulating...

November 6, 2020

Markets

SVB Leerink cuts Neovasc PT to $2 from $6

SVB Leerink slashed its price target for Neovasc (NASDAQ:NVCN) to $2 from $6, citing timing uncertainty for a U.S. launch of the company’s Reducer stent for percutaneous treatment of refractory angina. The stock closed...

November 6, 2020

Markets

SVB Leerink ups Inflarx to OP; PT to $10 from $7

SVB Leerink upgraded Inflarx (NASDAQ:IFRX) to “outperform” from “market perform” and raised its price target to $10 from $7, citing a “significant disconnect between the promise of IFX-1 in multiple applications, most...

November 6, 2020

Developments

LogicBio gets FDA fast track designation for methylmalonic acidemia

LogicBio Therapeutics’ (NASDAQ:LOGC) LB-001 received FDA fast track designation for the treatment of methylmalonic acidemia (MMA). MMA is caused by a mutation in genes responsible for the breakdown of certain proteins...

November 4, 2020

Developments

Cassava Sciences reports additional data from Phase 2b Alzheimer’s disease trial

Cassava Sciences (NASDAQ:SAVA) reported additional data from its Phase 2b study of sumifilam for the treatment of Alzheimer’s disease (AD). The study enrolled 64 patients with mild-to-moderate AD, 50-to-85 years of age...

November 4, 2020

Markets

HCW ups Syros to buy; PT to $15 from $11

H.C. Wainwright upgraded Syros Pharmaceuticals (NASDAQ:SYRS) to “buy” from “neutral” and upped its price target to $15 from $11, saying the company “has turned a corner, in our opinion.” The stock closed at $6.67 on Nov...

November 4, 2020

Subscribe